Cellular and molecular analyses of hematopoietic stem cell [HSC] interactions with bone marrow niches to improve HSC engraftment for transplantation and tolerance induction

造血干细胞 [HSC] 与骨髓微环境相互作用的细胞和分子分析,以改善 HSC 植入移植和耐受诱导

基本信息

  • 批准号:
    9753220
  • 负责人:
  • 金额:
    $ 37.43万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-08-01 至 2022-05-31
  • 项目状态:
    已结题

项目摘要

Project Summary We have shown that purified hematopoietic stem cells (HSC), first isolated by us, can be allotransplanted without GvH (they lack T cells), block autoimmune type 1 diabetes (and Systemic Lupus Erythematosus), and induce transplant tolerance to HSC donor tissues/organs. However, purified HSC transplantation is not used, in part due to the toxicity of the conditioning regimens. Therefore, it is vital that we improve our understanding of how HSCs interact with their local supporting environment—the hematopoietic niche. The goal of this research is to further identify and characterize the cellular and molecular components of the bone marrow (BM) HSC niche, and to understand how the ongoing inter-cellular communication between HSCs and their niche regulates their homing, anchoring, survival and function in health and in blood diseases. In previous versions of this grant we established antibodies in place of toxic regimens to condition recipients and will further modify the regimens to improve engraftment and accelerate reconstitution. Further, understanding the HSC-niche interaction has implications for stem cell competitions we have elucidated in pathology, for example, in hematopoietic disorders such as myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPN), and expansion of mutated clones to give clonal hematopoiesis, some that give rise to acute myeloid leukemia (AML). In the run-up to leukemia and MDS, clones of HSCs with pre-cancer mutations outcompete normal HSCs, but the total number of HSCs appears not to change, implying control of HSC numbers by the niche. The natural recirculation of HSCs allows highly competitive clones to dominate HSC niches throughout the body, so what we learn about normal HSC development and homing will also likely apply to a variety of disorders of hematopoiesis, including clonal hematopoiesis and leukemias. The experiments here concern HSC homing, anchoring, support, and niche competition. In Aim 1, we will utilize long-term (LT)-HSC reporter mice to explore the specificity of the niche, identify the cell types that form direct contact with LT-HSC, and analyze the adhesion molecules, cytokines and chemokines responsible for HSC and niche cross-talk. In Aim 2 we propose to understand the role of HSC-surrounding BM cells—focusing on adjacent sinusoidal endothelial cells and the essential BM stromal subsets and their expressed factors. That builds on our discovery and characterization of the skeletal stem cells (SSC), which clonally generate bone, cartilage, and several distinct BM stromal cells that support hematopoiesis. We plan to produce mice in which each cell subset in the niche, including HSC, can be engineered to knock out identified genes to decipher the complexity of niche-HSC interactions. This could lead to an understanding if there are means to increase the number of functional niches, whether modulation of the molecular interactions could clear the niche specifically to promote the HSC engraftment, and to provide targets for modulating clonal HSC expansions. !
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

IRVING L. WEISSMAN其他文献

IRVING L. WEISSMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('IRVING L. WEISSMAN', 18)}}的其他基金

NexTGen - STANFORD
NexTGen - 斯坦福
  • 批准号:
    10625700
  • 财政年份:
    2022
  • 资助金额:
    $ 37.43万
  • 项目类别:
Programmed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cells
巨噬细胞的程序性细胞去除(PrCR):靶细胞的识别和吞噬作用
  • 批准号:
    10576906
  • 财政年份:
    2020
  • 资助金额:
    $ 37.43万
  • 项目类别:
Programmed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cells
巨噬细胞的程序性细胞去除(PrCR):靶细胞的识别和吞噬作用
  • 批准号:
    10092925
  • 财政年份:
    2020
  • 资助金额:
    $ 37.43万
  • 项目类别:
Programmed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cells
巨噬细胞的程序性细胞去除(PrCR):靶细胞的识别和吞噬作用
  • 批准号:
    9888242
  • 财政年份:
    2020
  • 资助金额:
    $ 37.43万
  • 项目类别:
Programmed Cell Removal (PrCR) by Macrophages: recognition and phagocytosis of target cells
巨噬细胞的程序性细胞去除(PrCR):靶细胞的识别和吞噬作用
  • 批准号:
    10328484
  • 财政年份:
    2020
  • 资助金额:
    $ 37.43万
  • 项目类别:
Evolutionary Conserved Mechanisms of Neuronal Degeneration and Regeneration
神经元变性和再生的进化保守机制
  • 批准号:
    9979601
  • 财政年份:
    2020
  • 资助金额:
    $ 37.43万
  • 项目类别:
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
干细胞生物学、癌症干细胞生物学和癌症免疫治疗
  • 批准号:
    10247050
  • 财政年份:
    2017
  • 资助金额:
    $ 37.43万
  • 项目类别:
Stem Cell Biology, Cancer Stem Cell Biology, and Cancer Immunotherapy
干细胞生物学、癌症干细胞生物学和癌症免疫治疗
  • 批准号:
    10458105
  • 财政年份:
    2017
  • 资助金额:
    $ 37.43万
  • 项目类别:
Graduate Training in Stem Cell Biology and Regenerative Medicine
干细胞生物学和再生医学研究生培训
  • 批准号:
    10208896
  • 财政年份:
    2017
  • 资助金额:
    $ 37.43万
  • 项目类别:
A search for genes that regulate allogeneic stem cell competition
寻找调节同种异体干细胞竞争的基因
  • 批准号:
    8627187
  • 财政年份:
    2012
  • 资助金额:
    $ 37.43万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 37.43万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
    Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
  • 批准号:
    10699504
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
  • 批准号:
    10491642
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
  • 批准号:
    10782567
  • 财政年份:
    2023
  • 资助金额:
    $ 37.43万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了